Potential coverage of a multivalent M protein-based group A streptococcal vaccine
Potential coverage of a multivalent M protein-based group A streptococcal vaccine
复制标题
DOI：
10.1016/j.vaccine.2013.01.019
复制
发表时间：
2013-03-15
期刊：
影响因子：
5.5
通讯作者：
Kotloff, Karen L.
中科院分区：
文献类型：
--
作者：
Dale, James B.;Penfound, Thomas A.;Kotloff, Karen L.
背景资料：全球A组链球菌（GAS）疾病的最大负担是由于急性风湿热（ARF）和风湿性心脏病（RHD）。安全、有效和负担得起的疫苗旨在预防引发ARF的GAS感染，可降低RHD的全球总体发病率和死亡率。目前的研究使用来自马里巴马科学龄儿童的GAS分离株评估了一种新的30价M蛋白疫苗的潜在覆盖率，马里是RHD发展的高风险人群。方法：使用在巴马科咽炎流行病学研究期间回收的GAS分离株集合评估了兔抗血清对30价疫苗的杀菌活性。结果：评价了代表67种emm类型中的42种的单一分离株，占研究期间GAS感染的85%。收集的所有（14/14）疫苗emm类型被调理（杀菌杀死>50%），26/28非疫苗类型被调理。杀菌活性，观察到对60%的总EMM型回收在巴马科，占81%的所有infections.Conclusions：多价疫苗组成的N-末端M肽引起杀菌抗体对广泛的GAS血清型，表明其疗效可能会超出EMM型包括在疫苗中。(c)2013爱思唯尔有限公司保留所有权利。
Background: The greatest burden of group A streptococcal (GAS) disease worldwide is due to acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Safe, effective and affordable vaccines designed to prevent GAS infections that trigger ARF could reduce the overall global morbidity and mortality from RHD. The current study evaluated the potential coverage of a new 30-valent M protein-based vaccine using GAS isolates from school children in Bamako, Mali, a population at high risk for the development of RHD.Methods: The bactericidal activity of rabbit antisera against the 30-valent vaccine was assessed using a collection of GAS isolates recovered during a study of the epidemiology of pharyngitis in Bamako.Results: Single isolates representing 42 of 67 emm-types, accounting for 85% of the GAS infections during the study, were evaluated. All (14/14) of the vaccine emm-types in the collection were opsonized (bactericidal killing >50%) and 26/28 non-vaccine types were opsonized. Bactericidal activity was observed against 60% of the total emm-types recovered in Bamako, which accounted for 81% of all infections.Conclusions: Multivalent vaccines comprised of N-terminal M peptides elicit bactericidal antibodies against a broad range of GAS serotypes, indicating that their efficacy may extend beyond the emm-types included in the vaccine. (c) 2013 Elsevier Ltd. All rights reserved.